These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2176 related items for PubMed ID: 18687248

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, EMPIRIC Trial Investigators.
    J Am Coll Cardiol; 2006 Jul 18; 48(2):330-9. PubMed ID: 16843184
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.
    Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M, Pichlmaier AM, Lichtinghagen R, Geerlings H, Lippolt P, Niehaus M, Drexler H, Korte T.
    Europace; 2006 Aug 18; 8(8):618-24. PubMed ID: 16864615
    [Abstract] [Full Text] [Related]

  • 5. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM, TOVA Investigators.
    Circulation; 2004 Mar 23; 109(11):1386-91. PubMed ID: 14993132
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
    Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ.
    Circulation; 2005 Jun 07; 111(22):2898-905. PubMed ID: 15927965
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.
    Europace; 2014 Feb 07; 16(2):227-34. PubMed ID: 24108231
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia.
    Chen RH, Chen KP, Wang FZ, Hua W, Chen X, Zhang S.
    Chin Med J (Engl); 2006 Apr 05; 119(7):557-63. PubMed ID: 16620696
    [Abstract] [Full Text] [Related]

  • 14. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.
    Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ, PainFREE Rx II Investigators.
    Circulation; 2004 Oct 26; 110(17):2591-6. PubMed ID: 15492306
    [Abstract] [Full Text] [Related]

  • 15. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ, MADIT II Investigators.
    J Am Coll Cardiol; 2008 Apr 08; 51(14):1357-65. PubMed ID: 18387436
    [Abstract] [Full Text] [Related]

  • 16. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
    Saeed M, Neason CG, Razavi M, Chandiramani S, Alonso J, Natarajan S, Ip JH, Peress DF, Ramadas S, Massumi A.
    J Cardiovasc Electrophysiol; 2010 Dec 08; 21(12):1349-54. PubMed ID: 20561107
    [Abstract] [Full Text] [Related]

  • 17. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
    Grimm W, Plachta E, Maisch B.
    Pacing Clin Electrophysiol; 2006 Jul 08; 29(7):759-64. PubMed ID: 16884513
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, Zareba W, Steinberg JS, Fischer A, Ruskin J, Andrews ML, MADIT-II Research Group.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):769-73. PubMed ID: 16487843
    [Abstract] [Full Text] [Related]

  • 20. The implantable cardioverter defibrillator: technology, indications, and impact on cardiovascular survival.
    Bhatia A, Cooley R, Berger M, Blanck Z, Dhala A, Sra J, Axtell-Mcbride K, Vandervort C, Akhtar M.
    Curr Probl Cardiol; 2004 Jun 21; 29(6):303-56. PubMed ID: 15159713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 109.